This thought piece has been developed as part of an EFPIA project to drive awareness of the use of oncology-relevant endpoints in HTA body / payer decision-making. Oncology-relevant endpoints refer to all endpoints used in oncology clinical trials to measure outcomes relevant to patients. These can include, in addition to overall survival, patient-reported outcomes as well as progression-free survival in some metastatic settings, pathological complete response or event-free survival in ea
关注微信
